Cas:293302-19-9 3-[(3-tert-butyl-4-methoxyphenyl)methylidene]-1H-indol-2-one manufacturer & supplier

Chemical Name:3-[(3-tert-butyl-4-methoxyphenyl)methylidene]-1H-indol-2-one

CAS.NO:293302-19-9

Synonyms:3-(3-tert-Butyl-4-methoxybenzylidenyl)indolin-2-one

Molecular Formula:C₂₀H₂₁NO₂

Molecular Weight:307.38600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:38.33000

Exact Mass:307.15700

LogP:4.62340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-(3-tert-Butyl-4-methoxybenzylidenyl)indolin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(3-tert-Butyl-4-methoxybenzylidenyl)indolin-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-(3-tert-Butyl-4-methoxybenzylidenyl)indolin-2-one Use and application,3-(3-tert-Butyl-4-methoxybenzylidenyl)indolin-2-one technical grade,usp/ep/jp grade.

Related News: ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� 3-[(3-tert-butyl-4-methoxyphenyl)methylidene]-1H-indol-2-one manufacturer At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity. 3-[(3-tert-butyl-4-methoxyphenyl)methylidene]-1H-indol-2-one supplier At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity. 3-[(3-tert-butyl-4-methoxyphenyl)methylidene]-1H-indol-2-one vendor Taking Teva as an example, it has 2 large R & D centers and 3 professional R & D centers in 5 countries, which effectively supports the development of Teva’s generic pharmaceutical sector. 3-[(3-tert-butyl-4-methoxyphenyl)methylidene]-1H-indol-2-one factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.